ProCE Banner Activity

PARP Inhibitors for Targeting DNA Repair in Prostate Cancer

Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on PARP inhibition in patients with prostate cancer, including the clinical role of DNA damage repair genes and genetic testing, as well as optimal use of PARP inhibitors in the clinic.

Released: August 10, 2020

Expiration: August 09, 2021

Share

Faculty

Celestia S. Higano

Celestia S. Higano, MD, FACP

Professor
University of Washington
Departments of Urology and Medicine
Member
Fred Hutchinson Cancer Research Center
Seattle, Washington

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Learning Objectives

  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer including the poor prognosis in the absence of targeted treatment
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient DNA damage response
  • Interpret test results for predictive markers of PARP inhibitor benefit following evaluation of the available clinical evidence in CRPC harboring BRCA1/2 or other DNA damage response mutations
  • Select PARP inhibitor treatment for appropriate men with prostate cancer
  • Manage adverse events and other barriers to adherence from PARP inhibitors
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents in prostate cancer

Program Director Disclosure

Program Director

Celestia S. Higano, MD, FACP

Professor
University of Washington
Departments of Urology and Medicine
Member
Fred Hutchinson Cancer Research Center
Seattle, Washington

Celestia S. Higano, MD, FACP, has disclosed that she has received consulting fees from Clovis Oncology, Merck, and Pfizer and funds for research support from Clovis Oncology and Pfizer.

Faculty Disclosure

Primary Author

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Charles J. Ryan, MD, has disclosed that he has received consulting fees from Bayer, Janssen, and Sanofi Genzyme; has received funds for research support from Clovis Oncology and the Prostate Cancer Foundation; has received fees for non-CME/CE services from Janssen; and has served in a study leadership position for Clovis Oncology.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra D. Cravens, PhD, has no relevant conflicts of interest to report

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer reports that his spouse has ownership interest in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.